vertex pharmaceuticals inc. - VRTX
VRTX
Close Chg Chg %
502.55 -9.86 -1.96%
Closed Market
492.69
-9.86 (1.96%)
Volume: 1.28M
Last Updated:
Mar 28, 2025, 4:00 PM EDT
Company Overview: vertex pharmaceuticals inc. - VRTX
VRTX Key Data
| Open $504.79 | Day Range 491.37 - 504.79 |
| 52 Week Range 378.00 - 519.88 | Market Cap $129.05B |
| Shares Outstanding 256.79M | Public Float 256.02M |
| Beta 0.41 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.07 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.34M |
VRTX Performance
| 1 Week | -2.09% | ||
| 1 Month | 2.69% | ||
| 3 Months | 20.53% | ||
| 1 Year | 17.87% | ||
| 5 Years | 126.80% |
VRTX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
35
Full Ratings ➔
About vertex pharmaceuticals inc. - VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
VRTX At a Glance
Vertex Pharmaceuticals, Inc.
50 Northern Avenue
Boston, Massachusetts 02210
| Phone | 1-617-341-6100 | Revenue | 10.98B | |
| Industry | Pharmaceuticals: Major | Net Income | -535,600,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 11.641% | |
| Fiscal Year-end | 12 / 2025 | Employees | 6,100 | |
| View SEC Filings |
VRTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.455 |
| Price to Book Ratio | 6.305 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 21.793 |
| Enterprise Value to Sales | 9.057 |
| Total Debt to Enterprise Value | 0.018 |
VRTX Efficiency
| Revenue/Employee | 1,800,721.311 |
| Income Per Employee | -87,803.279 |
| Receivables Turnover | 6.825 |
| Total Asset Turnover | 0.476 |
VRTX Liquidity
| Current Ratio | 2.692 |
| Quick Ratio | 2.354 |
| Cash Ratio | 1.716 |
VRTX Profitability
| Gross Margin | 86.067 |
| Operating Margin | 39.686 |
| Pretax Margin | 2.262 |
| Net Margin | -4.876 |
| Return on Assets | -2.32 |
| Return on Equity | -3.152 |
| Return on Total Capital | -2.949 |
| Return on Invested Capital | -2.945 |
VRTX Capital Structure
| Total Debt to Total Equity | 10.661 |
| Total Debt to Total Capital | 9.634 |
| Total Debt to Total Assets | 7.577 |
| Long-Term Debt to Equity | 10.099 |
| Long-Term Debt to Total Capital | 9.126 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Vertex Pharmaceuticals Inc. - VRTX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 7.60B | 8.75B | 9.84B | 10.98B | |
Sales Growth
| +22.47% | +15.04% | +12.47% | +11.64% | |
Cost of Goods Sold (COGS) incl D&A
| 904.20M | 1.08B | 1.26B | 1.53B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 125.60M | 148.30M | 181.30M | 205.80M | |
Depreciation
| 125.60M | 148.30M | 167.80M | 160.40M | |
Amortization of Intangibles
| - | - | 1.70M | 20.20M | - |
COGS Growth
| +22.80% | +19.48% | +16.84% | +21.26% | |
Gross Income
| 6.70B | 7.67B | 8.58B | 9.45B | |
Gross Income Growth
| +22.42% | +14.44% | +11.85% | +10.23% | |
Gross Profit Margin
| +88.11% | +87.65% | +87.17% | +86.07% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 3.89B | 3.59B | 4.30B | 5.09B | |
Research & Development
| 3.05B | 2.64B | 3.16B | 3.63B | |
Other SG&A
| 840.10M | 944.70M | 1.14B | 1.46B | |
SGA Growth
| +49.66% | -7.80% | +19.85% | +18.49% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (1.60M) | 114.50M | 478.60M | 4.63B | |
EBIT after Unusual Expense
| 2.81B | 3.97B | 3.80B | (266.40M) | |
Non Operating Income/Expense
| (18.70M) | 321.30M | 625.20M | 545.50M | |
Non-Operating Interest Income
| 4.90M | 144.60M | 614.70M | 598.10M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 61.50M | 54.80M | 44.10M | 30.60M | |
Interest Expense Growth
| +5.76% | -10.89% | -19.53% | -30.61% | |
Gross Interest Expense
| 61.50M | 54.80M | 44.10M | 30.60M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 2.73B | 4.23B | 4.38B | 248.50M | |
Pretax Income Growth
| -12.40% | +55.01% | +3.48% | -94.33% | |
Pretax Margin
| +35.91% | +48.38% | +44.51% | +2.26% | |
Income Tax
| 388.30M | 910.40M | 760.20M | 784.10M | |
Income Tax - Current - Domestic
| 401.40M | 813.90M | 946.60M | 823.10M | |
Income Tax - Current - Foreign
| 141.50M | 372.40M | 350.10M | 309.80M | |
Income Tax - Deferred - Domestic
| (56.20M) | (415.00M) | (591.80M) | (487.40M) | |
Income Tax - Deferred - Foreign
| (98.40M) | 139.10M | 55.30M | 138.60M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 2.34B | 3.32B | 3.62B | (535.60M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 2.34B | 3.32B | 3.62B | (535.60M) | |
Net Income Growth
| -13.63% | +41.84% | +8.96% | -114.80% | |
Net Margin Growth
| +30.80% | +37.97% | +36.79% | -4.88% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 2.34B | 3.32B | 3.62B | (535.60M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 2.34B | 3.32B | 3.62B | (535.60M) | |
EPS (Basic)
| 9.0885 | 12.9715 | 14.0458 | -2.0768 | |
EPS (Basic) Growth
| -12.91% | +42.72% | +8.28% | -114.79% | |
Basic Shares Outstanding
| 257.70M | 256.10M | 257.70M | 257.90M | |
EPS (Diluted)
| 9.0115 | 12.8213 | 13.8948 | -2.0768 | |
EPS (Diluted) Growth
| -12.47% | +42.28% | +8.37% | -114.95% | |
Diluted Shares Outstanding
| 259.90M | 259.10M | 260.50M | 257.90M | |
EBITDA
| 2.93B | 4.23B | 4.46B | 4.57B | |
EBITDA Growth
| -1.61% | +44.10% | +5.44% | +2.39% | |
EBITDA Margin
| +38.59% | +48.34% | +45.32% | +41.56% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 506.192 | |
| Number of Ratings | 35 | Current Quarters Estimate | 4.267 | |
| FY Report Date | 03 / 2025 | Current Year's Estimate | 17.939 | |
| Last Quarter’s Earnings | 3.98 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.42 | Next Fiscal Year Estimate | 20.589 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 21 | 21 | 28 | 24 |
| Mean Estimate | 4.27 | 4.31 | 17.94 | 20.59 |
| High Estimates | 5.19 | 4.69 | 19.58 | 27.34 |
| Low Estimate | 2.75 | 3.25 | 13.96 | 17.91 |
| Coefficient of Variance | 10.56 | 6.94 | 6.47 | 10.67 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 19 | 20 | 22 |
| OVERWEIGHT | 1 | 1 | 0 |
| HOLD | 13 | 13 | 11 |
| UNDERWEIGHT | 2 | 2 | 2 |
| SELL | 0 | 0 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Vertex Pharmaceuticals Inc. - VRTX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Vertex Pharmaceuticals Inc. - VRTX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 7, 2025 | Ourania Tatsis EVP, Chief Reg. & Quality Off. | 54,481 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $485.49 per share | 26,449,980.69 |
| Mar 6, 2025 | David Matthew Altshuler EVP, Chief Scientific Officer | 29,743 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $490 per share | 14,574,070.00 |
| Mar 3, 2025 | Amit K. Sachdev EVP Chief Patient & Ext Af Off | 68,490 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share | 32,848,488.90 |
| Mar 3, 2025 | Stuart A. Arbuckle EVP, COO | 62,935 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share | 30,184,255.35 |
| Mar 3, 2025 | Edward Morrow Atkinson EVP, Chief Technical Ops. Off. | 22,002 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share | 10,552,379.22 |
| Mar 3, 2025 | Carmen Bozic EVP and CMO | 32,669 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share | 15,668,379.09 |
| Mar 3, 2025 | Edward Morrow Atkinson EVP, Chief Technical Ops. Off. | 19,352 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $475.34 per share | 9,198,779.68 |
| Mar 3, 2025 | Kristin Ambrose SVP & Chief Accounting Officer | 7,845 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share | 3,762,540.45 |
| Mar 3, 2025 | Charles F. Wagner EVP & Chief Financial Officer | 54,969 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share | 26,363,682.09 |
| Mar 3, 2025 | Ourania Tatsis EVP, Chief Reg. & Quality Off. | 58,539 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $475.34 per share | 27,825,928.26 |
| Mar 3, 2025 | David Matthew Altshuler EVP, Chief Scientific Officer | 32,974 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $480 per share | 15,827,520.00 |
| Mar 3, 2025 | Reshma Kewalramani CEO & President; Director | 105,915 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share | 50,797,893.15 |
| Feb 27, 2025 | Kristin Ambrose SVP & Chief Accounting Officer | 9,086 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $480.95 per share | 4,369,911.70 |
| Feb 20, 2025 | Nia Tatsis EVP, Chief Reg. & Quality Off. | 67,695 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $455.06 per share | 30,805,286.70 |
| Feb 20, 2025 | Jonathan Prim Biller EVP and Chief Legal Officer | 17,606 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $455.06 per share | 8,011,786.36 |
| Feb 20, 2025 | Nia Tatsis EVP, Chief Reg. & Quality Off. | 67,939 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $463.46 per share | 31,487,008.94 |
| Feb 20, 2025 | Jonathan Prim Biller EVP and Chief Legal Officer | 19,263 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $463.46 per share | 8,927,629.98 |
| Feb 20, 2025 | Jeffrey M. Leiden Executive Chairman; Director | 24,026 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $463.46 per share | 11,135,089.96 |
| Feb 7, 2025 | Amit K. Sachdev EVP Chief Patient & Ext Af Off | 72,647 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Reshma Kewalramani CEO & President; Director | 125,218 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
Vertex Pharmaceuticals Inc. in the News
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).